Medical Assistant resume example

• Acted as main point of contact for patients, doctors and hospital staff by closely reviewing medical charts and maintaining high levels of communication.
• Worked closely with patients to deliver excellent and direct individualized patient care.
• Worked with patients to schedule, appointments for office visits, tests and procedures.
• Completed documentation of care, hospital actions and patient activities.
• Maintained confidentiality of patient data and condition at all times to safeguard health information.
• Upheld confidentiality requirements and regulatory compliance guidelines in all areas.
• Delivered excellent patient experiences and direct care.

• Coordinated day-to-day clinic activities, including assignment of duties to experienced staff and orientation and training of less experienced clinic staff in specific clinic operations and procedures.
• Kept medical supplies in sufficient stock by monitoring levels and submitting replenishment orders before depleted.
• Documented patient care with electronic medical record and distributed relevant information to other medical providers to update diagnostic and treatment plans.
• Counseled patients via telephone according to established guidelines and protocols, advising on provider-established plans of care.
• Scheduled appointments for patients not requiring emergency services but needing examination from provider and consulting directly with provider as needed.
• Demonstrated ability to advocate for and strive to protect health, safety, and rights of patient.
• Followed all personal and health data procedures to effectively comply with HIPAA laws and prevent information breaches.
• Processed all FMLA/Disability forms.
• Collaborated with medical and administrative personnel to maintain patient-focused, engaging and compassionate environment.
• Assisted 6 MD's and 6 PA's to ensure optimal patient care.
• Conducted preliminary evaluations, including measuring weight, temperature and blood pressure, and documented results with accuracy.
• Performed venipuncture, EKG's, administered vaccinations , antibiotics , and assisted with minor wound care.
• Enhanced patient outcomes by providing knowledgeable education on procedures, medications and other physician instructions.
• Maintained research data, participant fields, regulatory binders and study databases.
• Performed administrative support duties.
• Assisted with regulatory binders and quality assurance and quality control procedures.
• Worked with principal investigator and sponsors to facilitate daily trial activities and comply with research protocols.
• Followed informed consent processes and maintained records.
• Maintained compliance with protocols covering patient care and clinical trial operations.
• Screened patient records, databases and physician referrals to identify prospective candidates for research studies.
• Participated in initiation visits and investigator meetings, implementing trials in accordance with study timelines and budgets.
• Gathered, processed and shipped lab specimens.
• Carried out day-day-day duties accurately and efficiently.

Research Experience

Medical Reasearch
• GS-US-292-0104: A Phase 3, Randomized, Double-Blind Study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus
Elvitegravir/Cobicistat//Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults. (Research Coordinator, 2013)
• GS-US-292-0109: A Phase 3, Open-Label Study to Evaluate Switching from a TDF- Containing Combination Regimen to a TAF- Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1, Positive Subjects. (Research Coordinator, 2013)
• GS-US-292-0\A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2013)
• GS-US-292-0119: A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alefenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1Positive Adults. (Research Coordinator, 2013)
• GS-US-311-1089: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. (Research Coordinator, 2014)
• GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Supressed, HIV-1Infected Subjects. (Research Coordinator, 2015)
• GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Supressed on Emtricitabine/Rilpivarine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). (Research Coordinator, 2015)
• GS-US-311-1717: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Supressed on Regimens Containing ABC/3TC. (Research Coordinator, 2015)
• GS-US-380-1489: A Phase 3, Randomized, double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2016)
• GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection. (Research Coordinator, 20016)itabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults. (Research Coordinator, 2013)

· GS-US-292-0109: A Phase 3, Open-Label Study to Evaluate Switching from a TDF- Containing Combination Regimen to a TAF- Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1, Positive Subjects. (Research Coordinator, 2013)

· GS-US-292-0111: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2013)

· GS-US-292-0119: A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alefenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1Positive Adults. (Research Coordinator, 2013)

· GS-US-311-1089: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. (Research Coordinator, 2014)

· GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Supressed, HIV-1Infected Subjects. (Research Coordinator, 2015)

· GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Supressed on Emtricitabine/Rilpivarine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). (Research Coordinator, 2015)

· GS-US-311-1717: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Supressed on Regimens Containing ABC/3TC. (Research Coordinator, 2015)

· GS-US-380-1489: A Phase 3, Randomized, double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2016)

· GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection. (Research Coordinator, 20016)